体内局部基因治疗隐性营养不良型大疱性表皮松解症:1期和2期试验
本研究评估含COL7A1的HSV-1载体B-VEC治疗隐性营养不良型大疱性表皮松解症(RDEB)皮肤。B-VEC在RDEB角质形成细胞、成纤维细胞、RDEB小鼠及人RDEB异种移植中恢复C7表达。随机安慰剂对照1期和2期试验纳入9例RDEB患者匹配伤口,每12周重复局部给药,未发生2级及以上B-VEC相关不良事件或载体脱落或组织结合皮肤免疫反应物,主要和次要目标达成。
要点
- B-VEC在RDEB角质形成细胞、成纤维细胞、RDEB小鼠及人RDEB异种移植中恢复C7表达。
- 随机安慰剂对照1期和2期试验纳入9例RDEB患者匹配伤口,每12周重复局部给药。
- 未发生2级及以上B-VEC相关不良事件或载体脱落或组织结合皮肤免疫反应物;主要和次要目标达成。
核心结论
- B-VEC是一种易于给药、安全耐受的局部分子矫正疗法,促进RDEB患者伤口愈合。
研究设计与样本
- 随机、安慰剂对照的1期和2期临床试验(NCT03536143),评估9例RDEB患者匹配伤口每12周重复局部给予B-VEC或安慰剂。
主要发现
- B-VEC在RDEB角质形成细胞、成纤维细胞、RDEB小鼠及人RDEB异种移植中恢复C7表达。
- 未发生2级及以上B-VEC相关不良事件或载体脱落或组织结合皮肤免疫反应物。
- HSV-1和C7抗体有时在基线时出现或B-VEC治疗后升高,对安全性或疗效无明显影响。
- C7表达、锚定原纤维组装、伤口表面积减少、伤口闭合持续时间及伤口闭合时间的主要和次要目标均达成。
关键数值与推荐
- 患者报告的疼痛严重程度次要结局因治疗伤口比例小未评估。
- 全局评估次要终点因与其他终点冗余未进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 患者报告的疼痛严重程度次要结局因治疗伤口比例小未评估。
- 全局评估次要终点因与其他终点冗余未进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDEB mice and human RDEB xenografts. Subsequently, a randomized, placebo-controlled, phase 1 and 2 clinical trial (NCT03536143) evaluated matched wounds from nine RDEB patients receiving topical B-VEC or placebo repeatedly over 12 weeks. No grade 2 or above B-VEC-related adverse events or vector shedding or tissue-bound skin immunoreactants were noted. HSV-1 and C7 antibodies sometimes presented at baseline or increased after B-VEC treatment without an apparent impact on safety or efficacy. Primary and secondary objectives of C7 expression, anchoring fibril assembly, wound surface area reduction, duration of wound closure, and time to wound closure following B-VEC treatment were met. A patient-reported pain-severity secondary outcome was not assessed given the small proportion of wounds treated. A global assessment secondary endpoint was not pursued due to redundancy with regard to other endpoints. These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.
引用
- Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022. PMID: 35347281. doi:10.1038/s41591-022-01737-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。